Dr. Paul Sax discusses an important change to the IAS-USA HIV treatment guidelines, in
HIV and ID Observations.
The IAS-USA Guidelines Panel has updated its recommendations on the use of injectable cabotegravir-rilpivirine for people with advanced HIV disease who are not able to take oral antiretroviral therapy. In the latest HIV and ID Observations, Dr. Paul Sax discusses the study results that led to this update.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.